Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing

14 May 2015

Abstract excerpt

Mutations in the serine/threonine kinase BRAF are found in more than 60% of melanomas. The most prevalent melanoma mutation is BRAF(V600E), which constitutively activates downstream MAPK signalling. Vemurafenib is a potent RAF kinase inhibitor with remarkable clinical activity in BRAF(V600E)-positive melanoma tumours. However, patients rapidly develop resistance to vemurafenib treatment. One resistance mechanism...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Adhesion Molecules Research
Share to Cytokine Signaling Pathways and Interactions
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25971842
DOI: 10.1038/ncomms8103

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicingPMID 25971842Read ↗

Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells.Semantic proximity Read ↗

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicingSemantic proximity Read ↗

Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanomaSemantic proximity Read ↗

Transcriptome-wide decoding the roles of aberrant splicing in melanoma MAPK-targeted resistance evolutionSemantic proximity Read ↗

miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanomaSemantic proximity Read ↗

Identification of pathways modulating Vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screenSemantic proximity Read ↗

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.Semantic proximity Read ↗

Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanomaSemantic proximity Read ↗

Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen.Semantic proximity Read ↗

Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant–Expressing MelanomaSemantic proximity Read ↗

miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in MelanomaSemantic proximity Read ↗

A molecular glue to take down mutant BRAF.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.